Multiple pharmaceutical companies on the STAR Market disclose R&D progress and major transaction developments simultaneously

LightningPacketLoss · 2026-03-09T11:48:59+00:00

On the evening of March 4th, several biotech companies listed on the STAR Market announced their latest R&D progress. Shengnuo Biotech received approval for the launch of Linalotide, Sunshine Nuohe obtained clinical trial approval for BTP4327, Kangwei Century's diagnostic reagent kit received medical device registration, Sanyou Medical's 3D-printed lumbar spine implants received FDA certification, and Shouyao Holdings adjusted its JAK2 inhibitor development partnership model.

LightningPacketLoss

2026-03-09 11:48:59

Abstract generation in progress

On the evening of March 4th, five biotech and pharmaceutical companies listed on the STAR Market—Chengdu Shengnuo Biotechnology Co., Ltd. (hereinafter referred to as “Shengnuo Bio”), Beijing Sunshine Nuohe Pharmaceutical Research Co., Ltd. (hereinafter referred to as “Sunshine Nuohe”), Jiangsu Kangwei Century Biotechnology Co., Ltd. (hereinafter referred to as “Kangwei Century”), Shanghai Sanyou Medical Devices Co., Ltd. (hereinafter referred to as “Sanyou Medical”), and Shouyao Holdings (Beijing) Co., Ltd. (hereinafter referred to as “Shouyao Holdings”)—collectively disclosed their research and development progress and major transaction updates.

Shengnuo Bio announced that its controlling subsidiary recently received the “Approval Notice for the Marketing Application of Linaclotide Raw Material” issued by the National Medical Products Administration (NMPA). This drug is mainly used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), and is the first medication with this mechanism of action for treating constipation.

Sunshine Nuohe announced that it and its subsidiaries received the “Drug Clinical Trial Approval Notice” approved by the NMPA. The clinical trial application for their research project BTP4327 has been approved, and the drug is intended for monotherapy in patients whose blood pressure cannot be sufficiently controlled.

Kangwei Century announced that its wholly owned subsidiary’s nine nucleic acid test kits for respiratory pathogens (using fluorescent PCR method) have received Class III “Medical Device Registration Certificate (In Vitro Diagnostic Reagents)” from the NMPA.

Sanyou Medical announced that its SWINGO-3DLumbarCageSystem (3D-printed lumbar interbody fusion system) has received FDA 510(k) certification, designed for use in conjunction with auxiliary internal fixation systems.

Shouyao Holdings disclosed an adjustment to the cooperative R&D model for a new anti-tumor drug JAK2 inhibitor. After the adjustment, in addition to the original milestone income of 3 million RMB stipulated in the agreement, Chia Tai Tianqing will also make two separate one-time payments totaling 80 million RMB to the company.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.